Hutchmed (China) initiates global phase A trial of HMPL-A830 in advanced solid tumors
Reuters brief says the company started the trial.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Hutchmed (China) Initiates Global Phase A Trial Of HMPL-A830 In Advanced Solid Tumors
HUTCHMED (China) Ltd HKEX:13
HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
First-in-class KRAS-payload leveraging synchronized EGFR inhibitionHONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 27, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the Phase Ia part of a global c…
HUTCHMED initiates global trial of HMPL-A830
HUTCHMED said it has initiated a global trial of its KRAS-EGFR antibody conjugate therapy HMPL-A830 in patients with solid tumors.